Treatment patterns, health state, and health care resource utilization of patients with radioactive iodine refractory differentiated thyroid cancer

Andrew G. Gianoukakis, Natalia M. Flores, Corey L. Pelletier, Anna Forsythe, Gregory R. Wolfe, Matthew Taylor

    Research output: Contribution to journalArticle

    3 Citations (Scopus)

    Abstract

    Background: Patients with differentiated thyroid cancer (DTC) often respond well to treatment but some become refractory to radioactive iodine (RAI) treatment, and treatment options are limited. Despite the humanistic and economic burden RAI refractory disease imposes on patients, published research concerning treatment patterns and health care resource utilization is sparse. Methods: Data were collected from an online retrospective chart review study in the US and five European Union (EU) countries (France, Germany, Italy, Spain, and UK) with physicians recruited from an online panel. Physicians (N=211) provided demographics, disease history, treatment information, and health care resource utilization for one to four of their patients with radioactive iodine refractory differentiated thyroid cancer (RR-DTC). Results: The majority of the patients with RR-DTC (N=623) were female (56%), and their mean age was 58.2 years. In this sample, 63.2% had papillary thyroid cancer and 57.0% were in Stage IV when deemed RAI refractory. Patients with RR-DTC experienced regional recurrence in the thyroid bed/central neck area (25.3%) and had distant metastatic disease (53.6%). At the time data were collected, 50.7% were receiving systemic treatment. Of those, 78.5% were on first-line treatment and 62.7% were receiving multikinase inhibitors. Regional differences for prescribed treatments were observed; the US was more likely to have patients receiving multikinase inhibitors (79.2%) compared with UK (41.2%) and Italy (17.1%). Additional details regarding treatment patterns and resource utilization are discussed. Conclusion: The current study aimed to obtain a greater understanding of RR-DTC treatment globally. These results can assist in the development and implementation of treatment guidelines and ultimately enhance the care of patients with RR-DTC.

    Original languageEnglish (US)
    Pages (from-to)67-76
    Number of pages10
    JournalCancer Management and Research
    Volume8
    DOIs
    StatePublished - May 30 2016

    Fingerprint

    Patient Acceptance of Health Care
    Health Resources
    Thyroid Neoplasms
    Iodine
    Health
    Therapeutics
    Italy
    Physicians
    European Union
    Spain
    France
    Germany
    Patient Care
    Thyroid Gland

    Keywords

    • Cost of illness
    • Disease burden
    • Therapy options
    • Thyroid cancer

    ASJC Scopus subject areas

    • Oncology

    Cite this

    Treatment patterns, health state, and health care resource utilization of patients with radioactive iodine refractory differentiated thyroid cancer. / Gianoukakis, Andrew G.; Flores, Natalia M.; Pelletier, Corey L.; Forsythe, Anna; Wolfe, Gregory R.; Taylor, Matthew.

    In: Cancer Management and Research, Vol. 8, 30.05.2016, p. 67-76.

    Research output: Contribution to journalArticle

    Gianoukakis, Andrew G. ; Flores, Natalia M. ; Pelletier, Corey L. ; Forsythe, Anna ; Wolfe, Gregory R. ; Taylor, Matthew. / Treatment patterns, health state, and health care resource utilization of patients with radioactive iodine refractory differentiated thyroid cancer. In: Cancer Management and Research. 2016 ; Vol. 8. pp. 67-76.
    @article{1eedc334bc694f3e947408e1dc07ffc0,
    title = "Treatment patterns, health state, and health care resource utilization of patients with radioactive iodine refractory differentiated thyroid cancer",
    abstract = "Background: Patients with differentiated thyroid cancer (DTC) often respond well to treatment but some become refractory to radioactive iodine (RAI) treatment, and treatment options are limited. Despite the humanistic and economic burden RAI refractory disease imposes on patients, published research concerning treatment patterns and health care resource utilization is sparse. Methods: Data were collected from an online retrospective chart review study in the US and five European Union (EU) countries (France, Germany, Italy, Spain, and UK) with physicians recruited from an online panel. Physicians (N=211) provided demographics, disease history, treatment information, and health care resource utilization for one to four of their patients with radioactive iodine refractory differentiated thyroid cancer (RR-DTC). Results: The majority of the patients with RR-DTC (N=623) were female (56{\%}), and their mean age was 58.2 years. In this sample, 63.2{\%} had papillary thyroid cancer and 57.0{\%} were in Stage IV when deemed RAI refractory. Patients with RR-DTC experienced regional recurrence in the thyroid bed/central neck area (25.3{\%}) and had distant metastatic disease (53.6{\%}). At the time data were collected, 50.7{\%} were receiving systemic treatment. Of those, 78.5{\%} were on first-line treatment and 62.7{\%} were receiving multikinase inhibitors. Regional differences for prescribed treatments were observed; the US was more likely to have patients receiving multikinase inhibitors (79.2{\%}) compared with UK (41.2{\%}) and Italy (17.1{\%}). Additional details regarding treatment patterns and resource utilization are discussed. Conclusion: The current study aimed to obtain a greater understanding of RR-DTC treatment globally. These results can assist in the development and implementation of treatment guidelines and ultimately enhance the care of patients with RR-DTC.",
    keywords = "Cost of illness, Disease burden, Therapy options, Thyroid cancer",
    author = "Gianoukakis, {Andrew G.} and Flores, {Natalia M.} and Pelletier, {Corey L.} and Anna Forsythe and Wolfe, {Gregory R.} and Matthew Taylor",
    year = "2016",
    month = "5",
    day = "30",
    doi = "10.2147/CMAR.S102383",
    language = "English (US)",
    volume = "8",
    pages = "67--76",
    journal = "Cancer Management and Research",
    issn = "1179-1322",
    publisher = "Dove Medical Press Ltd.",

    }

    TY - JOUR

    T1 - Treatment patterns, health state, and health care resource utilization of patients with radioactive iodine refractory differentiated thyroid cancer

    AU - Gianoukakis, Andrew G.

    AU - Flores, Natalia M.

    AU - Pelletier, Corey L.

    AU - Forsythe, Anna

    AU - Wolfe, Gregory R.

    AU - Taylor, Matthew

    PY - 2016/5/30

    Y1 - 2016/5/30

    N2 - Background: Patients with differentiated thyroid cancer (DTC) often respond well to treatment but some become refractory to radioactive iodine (RAI) treatment, and treatment options are limited. Despite the humanistic and economic burden RAI refractory disease imposes on patients, published research concerning treatment patterns and health care resource utilization is sparse. Methods: Data were collected from an online retrospective chart review study in the US and five European Union (EU) countries (France, Germany, Italy, Spain, and UK) with physicians recruited from an online panel. Physicians (N=211) provided demographics, disease history, treatment information, and health care resource utilization for one to four of their patients with radioactive iodine refractory differentiated thyroid cancer (RR-DTC). Results: The majority of the patients with RR-DTC (N=623) were female (56%), and their mean age was 58.2 years. In this sample, 63.2% had papillary thyroid cancer and 57.0% were in Stage IV when deemed RAI refractory. Patients with RR-DTC experienced regional recurrence in the thyroid bed/central neck area (25.3%) and had distant metastatic disease (53.6%). At the time data were collected, 50.7% were receiving systemic treatment. Of those, 78.5% were on first-line treatment and 62.7% were receiving multikinase inhibitors. Regional differences for prescribed treatments were observed; the US was more likely to have patients receiving multikinase inhibitors (79.2%) compared with UK (41.2%) and Italy (17.1%). Additional details regarding treatment patterns and resource utilization are discussed. Conclusion: The current study aimed to obtain a greater understanding of RR-DTC treatment globally. These results can assist in the development and implementation of treatment guidelines and ultimately enhance the care of patients with RR-DTC.

    AB - Background: Patients with differentiated thyroid cancer (DTC) often respond well to treatment but some become refractory to radioactive iodine (RAI) treatment, and treatment options are limited. Despite the humanistic and economic burden RAI refractory disease imposes on patients, published research concerning treatment patterns and health care resource utilization is sparse. Methods: Data were collected from an online retrospective chart review study in the US and five European Union (EU) countries (France, Germany, Italy, Spain, and UK) with physicians recruited from an online panel. Physicians (N=211) provided demographics, disease history, treatment information, and health care resource utilization for one to four of their patients with radioactive iodine refractory differentiated thyroid cancer (RR-DTC). Results: The majority of the patients with RR-DTC (N=623) were female (56%), and their mean age was 58.2 years. In this sample, 63.2% had papillary thyroid cancer and 57.0% were in Stage IV when deemed RAI refractory. Patients with RR-DTC experienced regional recurrence in the thyroid bed/central neck area (25.3%) and had distant metastatic disease (53.6%). At the time data were collected, 50.7% were receiving systemic treatment. Of those, 78.5% were on first-line treatment and 62.7% were receiving multikinase inhibitors. Regional differences for prescribed treatments were observed; the US was more likely to have patients receiving multikinase inhibitors (79.2%) compared with UK (41.2%) and Italy (17.1%). Additional details regarding treatment patterns and resource utilization are discussed. Conclusion: The current study aimed to obtain a greater understanding of RR-DTC treatment globally. These results can assist in the development and implementation of treatment guidelines and ultimately enhance the care of patients with RR-DTC.

    KW - Cost of illness

    KW - Disease burden

    KW - Therapy options

    KW - Thyroid cancer

    UR - http://www.scopus.com/inward/record.url?scp=84975047671&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84975047671&partnerID=8YFLogxK

    U2 - 10.2147/CMAR.S102383

    DO - 10.2147/CMAR.S102383

    M3 - Article

    AN - SCOPUS:84975047671

    VL - 8

    SP - 67

    EP - 76

    JO - Cancer Management and Research

    JF - Cancer Management and Research

    SN - 1179-1322

    ER -